© Oncology Nursing Society. Unauthorized reproduction, in part or in whole, is strictly prohibited. For permission to photocopy, post online, reprint, adapt, or otherwise reuse any or all content from this article, e-mail pubpermissions@ons.org. To purchase high-quality reprints, email reprints@ons.org.

 

April 2014, Volume 18, Number 2

 

Journal Club Article

Emerging Issues on the Impact of Smoking on Health-Related Quality of Life in Patients With Lung Cancer and Their Families

Karen Kane McDonnell, PhD, RN, OCN®, Linda F.C. Bullock, PhD, RN, FAAN, Patricia J. Hollen, PhD, RN, FAAN, Janie Heath, PhD, APRN-BC, FAAN, and Benjamin D. Kozower, MD, MPH

 

Compelling evidence exists that continued smoking after a diagnosis of lung cancer adversely affects treatment effectiveness, survival, risk of recurrence, second malignancy, and health-related quality of life (HRQOL). The importance of HRQOL to patients with cancer and their families has been well documented. Because of increasing evidence of the benefits of smoking cessation, more research has focused on the impact of smoking on HRQOL. Smoking is a behavior that clusters in families; patients who smoke are likely to have family members who smoke, and together they experience impaired HRQOL. This article describes the evidence regarding HRQOL measurement in individuals diagnosed with lung cancer and their family members who smoke and explores the implications for nursing practice. Oncology nurses are in a critical position to advocate for the integration of HRQOL assessment into clinical settings, monitor patient and family member smoking status and environmental tobacco smoke exposure, and support development of smoking cessation interventions to enhance HRQOL.

 

Lung cancer is the most common cancer worldwide. The five-year survival rate for individuals with lung cancer in the United States is 16%, but that percentage increases to 53% for individuals with localized lung cancer. Small cell lung cancer (SCLC) is less prevalent and has a lower five-year survival rate (6%) compared to non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer diagnoses and has an 18% five-year survival rate (American Cancer Society, 2013). With the advent of computed tomography screening procedures for the early detection of lung cancer, combined with improved treatments, the lung cancer survivor population is likely to increase (National Lung Screening Trial Research Team, 2011).

 

As a patient-reported outcome, health-related quality of life (HRQOL) is an important aspect of every patient’s condition, and a critical outcome in cancer treatment and research. HRQOL is a multidimensional and dynamic construct that typically incorporates the influences of physical, functional, psychological, social, and spiritual domains on an individual’s subjective perception of health and well-being (Gralla & Hollen, 2011).

 

Smoking and Lung Cancer

 

A substantial amount of research addresses the impact of smoking on HRQOL in the general population (Hays, Croghan, Baker, Cappelleri, & Bushmakin, 2010; Sarna, Bialous, Cooley, Jun, & Feskanich, 2008; Tillman & Silcock, 1997; Wilson, Parsons, & Wakefield, 1999). HRQOL is known to be lower in individuals who smoke cigarettes regularly, and even lower in those who smoke more heavily and for a longer time. Compelling evidence exists that continued smoking after a cancer diagnosis has adverse effects on HRQOL as well as on treatment effectiveness, survival, and risk of second malignancy or recurrence (Browman et al., 2002; Dresler & Gritz, 2001; Fox, Rosenzweig, & Ostroff, 2004; Jensen, Jensen, & Grau, 2007; Krueger & Rohrich, 2001; Moller, Villebro, Pedersen, & Tonnesen, 2008; Parson, Daley, Begh, & Aveyard, 2010). Most patients diagnosed with lung cancer have a smoking history, and many are current smokers (Cox, Africano, Tercyak, & Taylor, 2003; Park et al., 2012). Continued smoking after a cancer diagnosis was first associated with a poorer HRQOL in a study of 105 patients with head and neck cancer (Gritz et al., 1999). The results showed that, at the one-year follow-up, ex-smokers reported a higher HRQOL than patients who continued smoking.

 

Four reviews have examined HRQOL in relationship to lung cancer. The first review spanned 25 years (1970–1995) and confirmed the value of HRQOL measurements in this population. However, smoking status was not described (Montazeri, Gillis, & McEwen, 1998). Two other reviews examined HRQOL methodologies in randomized, controlled trials during a 30-year span (1980–2010). Smoking status was not described in those reviews either (Bottomley, Efficace, Thomas, Vanvoorden, & Ahmedzai, 2003; Claassens et al., 2011). Tobacco use and environmental tobacco smoke exposure have been described as the missing drug intervention in clinical trials because they often are undocumented or not considered as potential variables (Gritz, Dresler, & Sarna, 2005). In one cross-sectional study of cancer treatment intervention trials (N = 68), only 7% reported routine collection of tobacco use information at baseline and no trial reported monitoring tobacco use during treatment follow-up .

 

Only a few studies have examined HRQOL in patients with lung cancer who smoke. Fewer studies have examined the effect of smoking on the HRQOL of family members. A systematic review of seven studies and one abstract from 1995–2010 examined the effect of smoking on HRQOL in patients with lung cancer (Rowland, Eiser, Rowe, & Danson, 2012). Three studies showed that smokers reported significantly impaired HRQOL compared with patients who never smoked or quit smoking (Browning, Ferketich, Otterson, Reynolds, & Wewers, 2009; Garces et al., 2004, 2009). Since the Rowland et al. (2012) review, additional studies with significant findings have been published and will be included in this review. The purposes of this article are to describe the evidence of the impact of smoking cigarettes on HRQOL in patients with lung cancer and document emerging issues, including the impact of smoking on the HRQOL on family members, as well as environmental tobacco smoke exposure.

 

Symptomology of Lung Cancer and Smoking

 

Experts agree that the experience of symptoms and symptom distress affects HRQOL (Borneman & Economou, 2012). A small percentage (5%–10%) of patients with lung cancer are asymptomatic at diagnosis (Wozniak & Gadgeel, 2010). In others, presenting symptoms relate to local, regional, or distant effects of tumors. Cough, dyspnea, wheezing, chest discomfort or pain, bronchorrhea, and fatigue are common (Tyson, 2012). Lung cancer treatment (i.e., surgery, radiation, and chemotherapy) may improve or worsen symptoms. Symptoms may be exacerbated by smoking or tobacco withdrawal. Withdrawal elicits various physical and psychological symptoms that can temporarily intensify symptom burden (see Table 1). Most withdrawal symptoms manifest within the first 1–2 days, peak within one week, and subside within 2–4 weeks (University of California Regents, 2012). Overall, patients with lung cancer experience more symptom distress than patients with other cancer types (Cooley, 2000). Therefore, the patient’s smoking status and environmental tobacco smoke exposure should be considered as possible factors affecting the intensity of their symptoms.

 

Smoking Status and Tobacco Dependence

 

Although no universally accepted definition exists for smoking status or tobacco dependence, clearly describing and classifying research participants is crucial to understanding and translating findings. In clinical practice, defining smoking status helps accurately identify smokers, assess the impact of smoking, and recommend treatment. Most studies included in the systematic review by Rowland et al. (2012) organized smoking behavior into only three categories: current, former, and never. Some researchers included a score calculated using the Fagerström Test for Nicotine Dependence (Heatherton, Kozlowski, Frecker, & Fagerström, 1991) to ascertain additional information regarding nicotine dependence levels. In a study by Chen et al. (2012), smokers were categorized by the timing of smoking cessation: early quitters (more than one year prior to diagnosis), recent quitters (one year or less prior to diagnosis), late quitters (more than one year post-diagnosis), or never quit. Because nicotine addiction is a complex chronic illness, smoking status is likely to vary over time. For example, a patient with a suspicious mass may make a decision to stop smoking prior to surgery, only to relapse immediately after discharge. Therefore, assessing tobacco use and exposure at diagnosis and repeatedly throughout the continuum of care is important.

 

In addition, smoking status information usually is self-reported and smokers sometimes are reluctant to discuss their smoking status. Feelings of guilt and shame, fear of being stigmatized, or fatalism about their survival may influence the accuracy of self-reported smoking status (Cataldo, Jahan, & Pongquan, 2011). Biochemical verification sometimes is used to objectively measure and confirm smoking status. Several verification procedures assess the presence of cotinine using urine, blood, or saliva; other procedures assess expired carbon monoxide levels. The costs and benefits of objective measurement need to be considered to determine if they are justified (Gorber, Schofield-Hurwitz, Hardt, Levasseur, & Tremblay, 2009).

 

Health-Related Quality-of-Life Measurements

 

Evaluating HRQOL helps professional caregivers understand patient and family member experiences with the many issues involved in a cancer diagnosis. Measuring HRQOL also helps patients and family members to understand their own experiences over time and to communicate concerns. Numerous feasible, reliable, and valid HRQOL instruments exist. The Patient-Reported Outcome and Quality of Life Instruments Database (www.proqolid.org) lists more than 1,000 instruments. Instruments typically are classified as generic, disease-specific, or condition-specific. The current review used four HRQOL instruments (see Table 2). The Medical Outcomes Study SF-36® and SF-12® were used with patients and family members (Ware, 1996; Ware & Sherbourne, 1992). Disease-specific core measures included the Functional Assessment of Cancer Therapy–General (FACT-G) and the European Organisation for the Research and Treatment of Cancer Quality of Life Core 30 Questionnaire (EORTC QLQ-C30), version 3.0. Condition-specific instruments focus on symptoms and specifically evaluate lung cancer characteristics. The Lung Cancer Symptom Scale (LCSS) and two lung cancer modules (EORTC QLQ-LC13 and FACT-L [version 3.0]) were used in combination with their respective core measure (Aaronson et al., 1993; Bergman, Aaronson, Ahmedzai, Kaasa, & Sullivan, 1994; Cella et al., 1995; Hollen, Gralla, & Kris, 1994).

 

Findings

 

Four studies (see Table 3) used generic instruments (SF-36 and SF-12) with patients with pulmonary nodules or localized disease, short- and long-term survivors, as well as their family members (Lemonnier et al., 2011; Myrdal, Valtysdottir, Lambe, & Stahle, 2003; Sarna et al., 2006; Weaver, Rowland, Augustson, & Atienza, 2011). Two studies showed statistically significant findings. Patients with a pulmonary nodule who were current smokers had lower mean scores for all eight domains, regardless of whether the diagnosis was malignant or benign (Lemonnier et al., 2011). For patients with stages I or II lung cancer who underwent surgery, being a current smoker was associated with lower scores for mental health and vitality (Myrdal et al., 2003).

 

Seven studies used disease-specific instruments to measure HRQOL along the continuum of newly diagnosed to long-term survivors. In a study by Balduyck et al. (2011), 70 patients were recruited preoperatively and followed for 12 months postoperatively. Thirty-five were current smokers and six (8%) were recent quitters, meaning they had stopped smoking after diagnosis but before their surgery date. Recent quitters experienced a significantly greater burden of dyspnea at three months and longer impairment of physical functioning at six months. No return to baseline physical functioning, role, or social functioning occurred for current smokers, and a persistent increase in dyspnea occurred during a 12-month period. Among 1,028 long-term lung cancer survivors (77% localized disease), current smokers had significantly worse HRQOL than never smokers at six months to five years after diagnosis. Seven LCSS items (i.e., appetite, fatigue, cough, shortness of breath, lung cancer symptoms, illness affecting normal activities, and overall QOL) were clinically and statistically different for never smokers and current smokers (Garces et al., 2004). Fifty-one newly diagnosed current smokers (32% localized disease) were compared by disease stage and treatment status using the LCSS and FACT-L with long-term lung cancer survivors. The mean scores reported for the FACT-L and the LCSS corresponded to lower HRQOL (Browning et al., 2009). The largest sample of patients (N = 2,442) included 300 current smokers (13%) and 420 recent quitters (17%). Only one LCSS item was used to assess HRQOL. Clinically significant HRQOL deficits were reported by 510 (21%). Smoking status, smoking cessation, and pack years were associated with an overall HRQOL deficit within six months postdiagnosis (Sloan et al., 2012).

 

Only one study focused on patients with SCLC (N = 223, 38% with extensive disease). Current smokers (53%) were defined as those using tobacco within a year of diagnosis. Compared to a lung cancer-free group, current smoker status had a statistically significant impact on overall HRQOL and individual symptoms on the LCSS. Among those with SCLC, former smokers had the best HRQOL, recent quitters showed improvement, and late or never quitters reported the worst HRQOL (Chen et al., 2012).

 

Emerging Issues

 

Two studies expanded the scope of HRQOL research to include family members. Smoking is an important example of a health behavior that clusters in families (Ozakinci, Wells, Williams, Munro, & Donnelly, 2010). Evidence from one cooperative group study suggests that a patient with lung cancer who smokes has, on average, two relatives who smoke (Schilling et al., 1997). For one group of 50 survivors, only 4% were current smokers. However, their relatives were significantly more likely to continue smoking cigarettes (18%) and drink alcohol (71%) (Sarna et al., 2006). Smoking may be a concern for family members who live with patients with lung cancer (Weaver et al., 2011). One study explored the concordance of patient and family member smoking statuses and their effect on family member HRQOL. In 383 dyads of lung cancer survivors in which one or both members continued smoking, family members reported worse mental health (Weaver et al., 2011).

 

Environmental tobacco smoke is a carcinogen with serious short- and long-term health effects. Strong evidence suggests that no environmental tobacco smoke exposure level is risk-free (U.S. Department of Health and Human Services [USDHHS], 2006). Because of significant progress in restricting environmental tobacco smoke in public places and work sites, homes have become the predominant locations for environmental tobacco smoke exposure (USDHHS, 2006). Regardless of smoking status, exposing patients with lung cancer and their family members to environmental tobacco smoke may adversely affect HRQOL (Sarna et al., 2006). Only two studies examining HRQOL assessed environmental tobacco smoke. In one study of 51 dyads, 20% of lung cancer survivors and 42% of family members acknowledged environmental tobacco smoke exposure. In a smaller study, 21% of lung cancer survivors reported environmental tobacco smoke exposure that correlated with appetite loss on the EORTC QLQ-C30 (Ozturk, Sarihan, Ercan, & Karadag, 2009). Environmental tobacco smoke is known to cause coughing, wheezing, chest tightness, and reduced lung function in adults and should be considered a potential factor when assessing smoking status (USDHHS, 2006) and symptom burden.

 

Implications for Clinical Practice

 

Health-Related Quality-of-Life Assessment

 

Acquiring patient and family member input can assist the health-care team, including oncology nurses, with understanding the balance between perception of benefit and burden. Assessing HRQOL as part of routine clinical practice is an important new trend (Varricchio & Ferrans, 2010). In clinical settings, such assessments can aid in evaluating a response of interest, planning care, selecting interventions, facilitating informed treatment decisions, and enhancing care to maximize positive outcomes. Oncology nurses can be advocates for integrating HRQOL measurement into patient care settings. Gralla and Hollen (2011) outlined six steps to choosing an HRQOL instrument (see Table 4). In clinical settings, the instrument should be simple, efficient, and easy to score and interpret. The specific HRQOL information needed should guide instrument selection. For patients with lung cancer, an instrument incorporating symptom measurement may be most useful. The three lung cancer-specific HRQOL instruments (EORTC QLQ-LC13, LCSS, and FACT-L) have varying advantages. The EORTC QLQ-LC13 assesses disease-related symptoms and treatment toxicities, whereas the FACT-L measures psychosocial issues with less comprehensive symptom assessment; both are long questionnaires that may be considered burdensome. The LCSS does not address treatment toxicity but is shorter, simpler, and less burdensome (Earle & Weeks, 2005). For family members, a generic instrument is more appropriate.

 

Symptom Management and Palliative Care

 

Evidence suggests that patients with lung cancer who smoke experience greater symptom distress for a longer time period. Although the dimensions of HRQOL can be discussed separately (i.e., physical, functional, psychological, social, and spiritual), a dynamic interaction exists among them (Borneman & Economou, 2012). Disturbances in physical status and symptom occurrence directly affect all aspects of HRQOL (Leo et al., 2010). Physical concerns such as uncontrolled symptoms and decreased function affect psychological well-being by heightening anxiety, depression, and frustration (Fox & Lyon, 2006; Leo et al., 2010; Stark et al., 2002). For patients with lung cancer, using a lung cancer-specific HRQOL instrument in the clinical setting allows consistent assessment of essential domains so oncology nurses can facilitate adequate symptom management and make referrals to palliative care and other resources.

 

Smoking Cessation and Tobacco Smoke Exposure in the Environment

 

Smoking cessation benefits HRQOL to some degree for both patients and family members facing a lung cancer diagnosis, regardless of disease type, stage, or phase (newly diagnosed or survivor). The issue of environmental tobacco smoke exposure also needs more attention and evaluation.

 

Standardizing smoking status, exposure, and nicotine dependence assessment would strengthen the usefulness of such information in clinical practice (see Table 5). The evidence suggests that patients with cancer are not getting the assistance needed to stop smoking (Cooley et al., 2009; Morgan et al., 2011). Typically, patients with cancer who try to stop smoking do so without assistance, yielding low success rates (Schnoll et al., 2004). Many cancer treatment settings do not have formal smoking cessation programs. In addition, many health professionals are unaware of the evidence and believe it is too late or too stressful for patients with cancer to stop smoking (Bowles, Tuzzio, & Wiese, 2008; Gritz, Vidrine, & Lazev, 2003; Mazza et al., 2010). However, discussing the risks of continued smoking and the benefits of cessation at the time of diagnosis and over time are critical components of the educational process that surrounds the informed consent process related to treatment decision making. Patients generally do not know the health benefits of smoking cessation specific to the course of their cancer (Ostroff & Dhingra, 2007). Family members also may lack understanding of the impact of their smoking on the patient’s health and ability to remain abstinent (Gritz, Nisenbaum, Elashoff, & Holmes, 1991; Ostroff & Dhingra, 2007).

 

Oncology nurses can play essential roles in the assessment, intervention, and evaluation of smoking cessation practices in clinical settings (Sarna, Bialous, Chan, Hollen, & O’Connell, 2012). Patients with lung cancer and their family members may have higher nicotine dependence levels, more difficulty quitting, and greater stress and emotional distress, thereby suggesting the need for tailored and more intensive interventions (Cataldo, Dubey, & Prochaska, 2010). Given the known risk of environmental tobacco smoke exposure, families should be encouraged to establish smoke-free homes. Many valuable educational resources are available for nurses and patients (see Figure 1). Within diverse practice settings, oncology nurses can readily offer compelling advice to patients and family members about the risks of continued smoking and environmental tobacco smoke exposure as well as the benefits of quitting (Sarna et al., 2012).

 

Conclusion

 

Oncology nurses should reflect on the strengths and limitations of research and carefully consider the value of the evidence. Interventions designed to enhance HRQOL may lead to improved HRQOL and other positive outcomes (Sloan, 2011). Continued integration of HRQOL assessment into clinical settings, palliative care programs that assess smoking status and environmental tobacco smoke exposure of all patients with cancer, and availability of smoking cessation programs for patients and family members who smoke will transform the care of patients with lung cancer and their families.

 

Implications for Practice

 

Ø  Advocate for the integration of a health-related quality-of-life assessment into clinical settings.

 

Ø  Monitor patient and family member smoking status and environmental smoke exposure.

 

Ø  Support development of cessation interventions to enhance health-related quality of life.

 

References

 

Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., . . . Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.

 

American Cancer Society. (2013). Cancer facts and figures, 2013. Atlanta, GA: Author.

 

Balduyck, B., Sardari Nia, P., Cogen, A., Dockx, Y., Lauwers, P., Hendriks, J., & Van Schil, P. (2011). The effect of smoking cessation on quality of life after lung cancer surgery. European Journal of Cardiothoracic Surgery, 40, 1432–1438.

 

Bergman, B., Aaronson, N.K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). EORTC study group on quality of life. The EROTC QLQ-LC13: A modular supplement to the EORTC core quality questionnaire (QLQ-C30) for use in lung cancer trials. European Journal of Cancer, 30, 635–642.

 

Borneman, T., & Economou, D. (2012). Quality of life and symptoms. In C. King and P. Hinds (Eds.), Quality of life, from nursing and patient perspectives (3rd ed., pp. 197–212). Sudbury, MA: Jones and Bartlett Learning.

 

Bottomley, A., Efficace, F., Thomas, R., Vanvoorden, V., & Ahmedzai, S.H. (2003). Health-related quality of life in non-small cell lung cancer: Methodologic issues in randomized controlled trials. Journal of Clinical Oncology, 21, 2982–2992.

 

Bowles, E.J., Tuzzio, L., & Wiese, C.J. (2008). Understanding high-quality cancer care. Cancer, 112, 934–942.

 

Browman, G.P., Mohide, E.A., Willian, A., Hodson, I., Wong, G., Grimard, L., . . . Farrell, S. (2002). Association between smoking during radiotherapy and prognosis in head and neck cancer: A follow-up study. Head and Neck, 24, 1031–1037.

 

Browning, K.K., Ferketich, A.O., Otterson, G.A., Reynolds, N.R., & Wewers, M.E. (2009). A psychometric analysis of quality of life tools in lung cancer patients who smoke. Lung Cancer, 66, 134–139.

 

Cataldo, J.K., Dubey, S., & Prochaska, J.J. (2010). Smoking cessation: An integral part of lung cancer treatment. Oncology, 78, 289–301. http://dx.doi.org/10.1159/000319937

 

Cataldo, J.K., Jahan, T., & Pongquan, V. (2011). Lung cancer stigma, depression, and quality of life among ever and never smokers. European Journal of Oncology Nursing, 16, 264–269. http://dx.doi.org/10.1016/j.ejon.2011.06.008

 

Cella, D., Bonomi, A., Lloyd, S., Tulsky, D., Kaplan, E., & Bonomi, P. (1995). Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer, 12, 199–220.

 

Chen, J., Qi, Y., Wampfler, J.A., Jatoi, A., Garces, Y.I., Busta, A.J., . . . Yang, P. (2012). Effect of cigarette smoking on quality of life in small cell lung cancer patients. European Journal of Cancer, 48, 1593–1601.

 

Claassens, L., van Meerbeeck, J., Coens, C., Quinten, C., Ghislain, I., Sloan, E.K., . . . Bottomley, A. (2011). Health-related quality of life in non-small cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. Journal of Clinical Oncology, 29, 2104–2120.

 

Cooley, M.E. (2000). Symptoms in adults with lung cancer: A systematic research review. Journal of Pain and Symptom Management, 19, 137–153.

 

Cooley, M.E., Sarna, L., Kolterman, J., Lukanich, J.M., Jaklitsch, M., Green, S.B., . . . Bueno, R. (2009). Smoking cessation is challenging even for patients recovering from lung cancer surgery with curative intent. Lung Cancer, 66, 218–225.

 

Cox, L., Africano, N., Tercyak, K., & Taylor, K. (2003). Nicotine dependence treatment for patients with cancer. Cancer, 98, 632–644.

 

Dresler, C., & Gritz, E. (2001). Smoking, smoking cessation, and the oncologist. Lung Cancer, 34, 315–323.

 

Earle, C.C., & Weeks, J.C. (2005). The science of quality-of-life measurement in lung cancer. In J. Lipscomb, C.C. Gotay, & C. Synder (Eds.), Outcomes assessment in cancer: Measures, methods, and applications (pp. 160–177). Cambridge, England: Cambridge University Press.

 

Fox, J., Rosenzweig, K., & Ostroff, J. (2004). The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer, 44, 287–293.

 

Fox, S.W., & Lyon, D.E. (2006). Symptom clusters and quality of life in survivors of lung cancer. Oncology Nursing Forum, 33, 931–936. http://dx.doi.org/10.1188/06.ONF.931-936

 

Garces, Y.I., Szydlo, D.W., Sarna, L., Clark, M.M., Sloan, J.A., & Yang, P. (2009). The impact of smoking behavior on quality of life among long term survivors of lung cancer [Abstract]. Journal of Thoracic Oncology, 4, S308.

 

Garces, Y.I., Yang, P., Parkinson, J., Zhao, X., Wampfler, J.A., Ebbert, J.O., & Sloan, J.A. (2004). The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest, 126, 1733–1741.

 

Gorber, S.C., Schofield-Hurwitz, S., Hardt, J., Levasseur, G., & Tremblay, M. (2009). The accuracy of self-reported smoking: A systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine and Tobacco Research, 11, 12–24.

 

Gralla, R.J., & Hollen, P.J. (2011). Quality-of-life assessments: The challenge of incorporating quality-of-life and patient-reported outcomes into investigative trials and clinical practice. In I.N. Oliver (Ed.), The MASCC textbook of cancer supportive care and survivorship (pp. 63–70). New York, NY: Springer.

 

Gritz, E., Dresler, C., & Sarna, L. (2005). Smoking, the missing drug intervention in clinical trials: Ignoring the obvious. Cancer Epidemiology, Biomarkers and Prevention, 14, 2287–2293.  http://dx.doi.org/10.1158/1055-9965.EPI-05-0224

 

Gritz, E.R., Carmack, C.L., de Moor, C., Coscarelli, A., Schacherer, C.W., Meyers, E.G., & Abemayor, E. (1999). First year after head and neck cancer: Quality of life. Journal of Clinical Oncology, 17, 352–360.

 

Gritz, E.R., Nisembaum, R., Elashoff, R., & Holmes, E. (1991). Smoking behaviors following diagnosis of patients with stage I non-small cell lung cancer. Cancer Causes and Control, 2, 105–112.

 

Gritz, E.R., Vidrine, D.J., & Lazev, A.B. (2003). Smoking cessation in cancer patients: Never too late to quit. In C. Given, B. Given, V. Champion, S. Kozachik, & D.N. DeVoss (Eds.), Evidenced-based cancer care and prevention: Behavioral interventions (pp. 107–140). New York, NY: Springer.

 

Hays, J.T., Croghan, I.T., Baker, C.L., Cappelleri, J.C., & Bushmakin, A. (2010). Changes in health-related quality of life with smoking cessation treatment. European Journal of Public Health, 22, 224–229. http://dx.doi.org/10.1093/eurpub/ckq137

 

Heatherton, T.F., Kozlowski, L.T., Frecker, R.C., & Fagerstrom, K.O. (1991). The Fagerstom Test for Nicotine Dependence: A revision of the Fagerstrom tolerance questionnaire. British Journal of Addiction, 86, 1119–1127.

 

Hollen, P., Gralla, R.J., & Kris, M.G. (1994). Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the Lung Cancer Symptom Scale. Cancer, 73, 2087–2098.

 

Jensen, J., Jensen, N., & Grau, M. (2007). Smoking has a negative impact upon health-related quality of life after treatment for head and neck cancer. Oral Oncology, 43, 187–192.

 

Krueger, J., & Rohrich, R. (2001). Clearing the smoke: The scientific rationale for tobacco abstention with plastic surgery. Plastic and Reconstructive Surgery, 108, 1063–1073.

 

Lemonnier, I., Baumann, C., Jolly, D., Arveux, P., Woronoff-Lemsi, M., Velten, M., & Guillemin, F. (2011). Solitary pulmonary nodules: Consequences for patient quality of life. Quality of Life Research, 20, 101–109.

 

Leo, F., Scanagatta, P., Vannucci, F., Brambilla, D., Radice, D., & Spaggiari, L. (2010). Impaired quality of life after pneumonectomy: Who is at risk? Journal of Thoracic and Cardiovascular Surgery, 139, 49–52.

 

Mazza, R., Lina, M., Boffi, R., Invernizzi, C., De Marco, C., & Pierotti, M. (2010). Taking care of the smoker cancer patients: A review and some recommendations. Annals of Oncology, 21, 1404–1409. http://dx.doi.org/10.1093/annonc/mdp599

 

Moller, A.M., Villebro, N., Pedersen, T., & Tonnesen, H. (2008). Effect of preoperative smoking intervention on postoperative complications: A randomized clinical trial. Lancet, 359, 114–117.

 

Montazeri, A., Gillis, C.R., & McEwen, J. (1998). Quality of life in patients with lung cancer: A review of the literature from 1970–1995. Chest, 113, 467–481.

 

Morgan, G., Schnoll, R.A., Alfano, C.M., Evans, S.E., Goldstein, A., Ostroff, J., . . . Cox, L.S. (2011). National Cancer Institute conference on treating tobacco dependence at cancer centers. Journal of Oncology Practice, 7, 178–182. http://dx.doi.org/10.1200/JOP.2010.000175

 

Myrdal, G., Valtysdottir, S., Lambe, M., & Stahle, E. (2003). Quality of life following lung cancer surgery. Thorax, 58, 194–197.

 

National Lung Screening Trial Research Team. (2011). Reducing lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365, 395–409. http://dx.doi.org/10.1056/NEJMoa1102873

 

Ostroff, J., & Dhingra, L.K. (2007). Smoking cessation and cancer survivors. In M. Feuerstein (Ed.), Handbook of cancer survivors (pp. 303–322). New York, NY: Springer.

 

Ozakinci, G., Wells, M., Williams, B., Munro, A.J., & Donnelly, P. (2010). Cancer diagnosis: An opportune time to help patients and their families stop smoking? Public Health, 124, 479–482.

 

Ozturk, A., Sarihan, S., Ercan, I., & Karadag, M. (2009). Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy. American Journal of Clinical Oncology, 32, 65–72.

 

Park, E.R., Japuntich, S.J., Rigotti, N.A., Traeger, L., He, Y., Wallace, R.B., . . . Keating, N.L. (2012). A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer, 118, 3153–3164.

 

Parson, A., Daley, A., Begh, R., & Aveyard, P. (2010). Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: Systematic review of observational studies with meta-analysis. BMJ, 340, 55–69.

 

Rowland, C., Eiser, C., Rowe, R., & Danson, S. (2012). The effect of smoking on health-related quality of life in lung cancer patients: A systematic review. BMJ Supportive and Palliative Care. Retrieved from http://spcare.bmj.com/content/2/4/312

 

Sarna, L., Bialous, S.A., Chan, S.C., Hollen, P., & O’Connell, K.A. (2012). Making a difference: Nursing scholarship and leadership in tobacco control. Nursing Outlook. Retrieved from http://www.sciencedirect.com/science/article/pii/S0029655412000966

 

Sarna, L., Bialous, S.A., Cooley, M.E., Jun, H., & Feskanich, D. (2008). Impact of smoking and smoking cessation on health-related quality of life in women in the Nurses’ Health Study. Quality of Life Research, 17, 1217–1227.

 

Sarna, L., Cooley, M.E., Brown, J.K., Williams, R.D., Chernecky, C., Padilla, G., & Danao, L.L. (2006). Quality of life and health status of dyads of women with lung cancer and family members. Oncology Nursing Forum, 33, 1109–1116.

 

Schilling, A., Conaway, M.R., Wingate, P.J., Atkins, J.N., Berkowitz, I.M., Clamon, G.H., . . . Vinciguerra, V. (1997). Recruiting cancer patients to participate in motivating their relatives to quit smoking. A cancer control study of the Cancer and Leukemia Group B (CALGB 9072). Cancer, 79, 152–160.

 

Schnoll, R.A., Rothman, R.L., Newman, H., Lerman, C., Miller, S.M., Movsas, B., . . . Cheng, J. (2004). Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: Implications for the development of tobacco control programs for cancer patients. Psycho-Oncology, 13, 346–358.

 

Sloan, J.A. (2011). Metrics to assess quality of life after management of early-stage lung cancer. Cancer Journal, 17, 63–67.

 

Sloan, J.A., Zhao, X., Novotny, P.J., Wampfler, J., Garces, Y., Clark, M.M., & Yang, P. (2012). Relationship between deficits in overall quality of life and non-small cell lung cancer survival. Journal of Clinical Oncology, 30, 1498–1504.

 

Stark, D., Kiely, M., Smith, A., Velikova, G., House, A., & Selby, P. (2002). Anxiety disorders in cancer patients: Their nature, associations, and relation to quality of life. Journal of Clinical Oncology, 20, 3137–3148.

 

Tillman, M., & Silcock, J.A. (1997). A comparison of smokers’ and nonsmokers’ health-related quality of life. Journal of Public Health Medicine, 19, 268–273.

 

Tyson, L.B. (2012). Clinical presentation and diagnostic evaluation. In N. Houlihan & L. Tyson (Eds.), Lung cancer (2nd ed., pp. 47–57). Pittsburgh, PA: Oncology Nursing Society.

 

University of California Regents. (2012). Rx for change: Clinician-assisted tobacco cessation. Retrieved from http://rxforchange.ucsf.edu

 

U.S. Department of Health and Human Services. (2006). The health consequences of involuntary exposure to tobacco smoke: A report of the Surgeon General. Retrieved from http://www.surgeongeneral.gov/library/reports/secondhandsmoke

 

Varricchio, C.G., & Ferrans, C.E. (2010). Quality of life assessments in clinical practice. Seminars in Oncology Nursing, 20, 12–17.

 

Ware, J.E. (1996). A 12-item short form health survey: Construction of scales and preliminary tests. Medical Care, 34, 220–233.

 

Ware, J.J., & Sherbourne, C.D. (1992). The MOS 36-item Short-Form Health Survey (SF-36): Conceptual framework and item selection. Medical Care, 30, 473–783.

 

Weaver, K.E., Rowland, J.H., Augustson, E., & Atienza, A.A. (2011). Smoking concordance in lung and colorectal cancer: Patient-caregivers dyads and quality of life. Cancer Epidemiology, Biomarkers and Prevention, 20, 239–248.

 

Wilson, D., Parsons, J., & Wakefield, M. (1999). The health-related quality of life of never smokers, ex-smokers, and light, moderate, and heavy smokers. Prevention Medicine, 29, 139–144.

 

Wozniak, A.J., & Gadgeel, S.M. (2010). Clinical presentation of non-small cell carcinoma of the lung. In H.I. Pass, D.P. Carbone, D.H. Johnson, J.D. Minna, G.V. Scagliotti, & A.T. Turrisi, III (Eds.), Principles and practice of lung cancer (4th ed., pp. 327–340). Philadelphia, PA: Lippincott Williams and Wilkins.

 

Use This Article in Your Next Journal Club

 

Karen Kane McDonnell, PhD, RN, OCN®, is an assistant professor of nursing in the College of Nursing at the University of South Carolina in Columbia; Linda F.C. Bullock, PhD, RN, FAAN, is the associate dean for research, Patricia J. Hollen, PhD, RN, FAAN, is a professor, Janie Heath, PhD, APRN-BC, FAAN, is the associate dean of Academic Programs, all in the School of Nursing, and Benjamin D. Kozower, MD, MPH, is an associate professor of surgery in the University of Virginia Health System, all at the University of Virginia in Charlottesville. The authors take full responsibility for the content of the article. Funding was provided through a doctoral degree scholarship in cancer nursing from the American Cancer Society (No. 121284-DSCN-11-199-01-SCN). The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or editorial staff. McDonnell can be reached at karenkm@mailbox.sc.edu, with copy to editor at CJONEditor@ons.org. (Submitted May 2013. Revision submitted August 2013. Accepted for publication August 8, 2013.)

 

Key words: lung cancer; smoking; health-related quality of life

 

http://dx.doi.org/10.1188/14.CJON.18-02AP